

FOR IMMEDIATE RELEASE Aug. 12, 2020

News Release

VA Providence Healthcare System
Ocean State Research Institute, Inc.
830 Chalkstone Ave
Providence, RI 02908
Contact: Winfield S. Danielson III

401-273-7100 ext. 3369 winfield.danielsoniii@va.gov

Study on Synchronized Transcranial Magnetic Stimulation for Substance Use Disorder

PROVIDENCE, R.I. – A research scientist and staff psychologist at the <u>VA RR&D Center for Neurorestoration and Neurotechnology</u> at the Providence VA Medical Center, and Associate Professor of Psychiatry and Human Behavior at the Warren Alpert Medical School at Brown University, received an award July 1 for a two-year research study from the VA Office of Rehabilitation Research and Development.

Dr. John McGeary's project, titled "Synchronized Transcranial Magnetic Stimulation for Substance Use-Disordered Veterans," will evaluate the acceptability, tolerability and safety of synchronized TMS as a potential treatment for substance use disorders.

The nearly \$200,000 study will allow McGeary and his team at the Providence VA Medical Center, which includes leaders in neurostimulation – Dr. Noah Philip, chief of Psychiatric Neuromodulation – and addiction treatment – Dr. Robert Swift, chief of Mental Health and Behavioral Science Services – to take key first steps to developing a potential new treatment for opiate use disorder, cocaine use disorder, and alcohol use disorder.

"As the response to the COVID-19 pandemic created challenges for traditional forms of addiction treatment, it is more important than ever to develop new treatments, particularly ones that could be used in a home setting," said McGeary. "There are currently no FDA-approved treatments for cocaine use disorder, so this technology could be a critically important tool for treatment in these cases as well, if the research supports its use."

Study on Synchronized TMS for Substance Use – 2 of 2



Photo demonstrating the use of a Synchronized Transcranial Magnetic Stimulation device in a home setting (photo courtesy of Wave Neuroscience Inc.).